Background: Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking. Objectives: To assess the d
Shi Yu Derek Lim,1 Hazel H Oon21Internal Medicine Residency, National Healthcare Group, Singapore, S...
Publication of real world data on the results of treatment with (approved) drugs is important to all...
Treatment of hidradenitis suppurativa (HS) is often unsatisfactory. The efficacy of infliximab for t...
Background: Biologics are often required for the treatment of hidradenitis suppurativa (HS). However...
Importance: Biologics are important in treating patients with hidradenitis suppurativa (HS). However...
Background Biologics are often required for the treatment of hidradenitis suppurativa (HS). However,...
The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-sev...
Background: The treatment guidelines for hidradenitis suppurativa (HS) vary among different countrie...
: To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenit...
Given the absence of significant improvement in the treatment of hidradenitis suppurativa (HS) with ...
The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-sev...
ABSTRACT Hidradenitis suppurativa (HS) is a chronic debilitating inflammatory skin disease character...
Adalimumab is the only biologic agent approved for the treatment of moderate-to-severe hidradenitis ...
Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a re...
Shi Yu Derek Lim,1 Hazel H Oon21Internal Medicine Residency, National Healthcare Group, Singapore, S...
Publication of real world data on the results of treatment with (approved) drugs is important to all...
Treatment of hidradenitis suppurativa (HS) is often unsatisfactory. The efficacy of infliximab for t...
Background: Biologics are often required for the treatment of hidradenitis suppurativa (HS). However...
Importance: Biologics are important in treating patients with hidradenitis suppurativa (HS). However...
Background Biologics are often required for the treatment of hidradenitis suppurativa (HS). However,...
The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-sev...
Background: The treatment guidelines for hidradenitis suppurativa (HS) vary among different countrie...
: To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenit...
Given the absence of significant improvement in the treatment of hidradenitis suppurativa (HS) with ...
The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-sev...
ABSTRACT Hidradenitis suppurativa (HS) is a chronic debilitating inflammatory skin disease character...
Adalimumab is the only biologic agent approved for the treatment of moderate-to-severe hidradenitis ...
Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a re...
Shi Yu Derek Lim,1 Hazel H Oon21Internal Medicine Residency, National Healthcare Group, Singapore, S...
Publication of real world data on the results of treatment with (approved) drugs is important to all...
Treatment of hidradenitis suppurativa (HS) is often unsatisfactory. The efficacy of infliximab for t...
DOI
Add to ORKG